Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-04-04
1999-11-30
Trinh, Ba K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549475, 549497, 549504, A61K 3134, C07D30712, C07D30714
Patent
active
059943971
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to novel compounds and compositions, and methods of their use in the treatment of glaucoma and ocular hypertension. In particular, the present invention relates to the use of certain substituted tetrahydrofuran analogs of D and F series prostaglandins to treat glaucoma and ocular hypertension.
Glaucoma is a progressive disease which leads to optic nerve damage, and, ultimately, total loss of vision. The causes of this disease have been the subject of extensive studies for many years, but are still not fully understood. The principal symptom of and/or risk factor for the disease is elevated intraocular pressure or ocular hypertension due to excess aqueous humor in the anterior chamber of the eye.
The causes of aqueous humor accumulation in the anterior chamber are not fully understood. It is known that elevated intraocular pressure ("IOP") can be at least partially controlled by administering drugs which reduce either the production of aqueous humor within the eye, such as beta-blockers and carbonic anhydrase inhibitors, or increase the flow of aqueous humor out of the eye, such as miotics and sympathomimetics.
Most types of drugs conventionally used to treat glaucoma have potentially serious side effects. Miotics such as pilocarpine can cause blurring of vision and other visual side effects, which may lead either to decreased patient compliance or to termination of therapy. Systemically administered carbonic anhydrase inhibitors can also cause serious side effects, such as nausea, dyspepsia, fatigue, and metabolic acidosis, which side effects can affect patient compliance and/or necessitate the termination of treatment. Moreover, some beta-blockers have increasingly become associated with serious pulmonary side effects attributable to their effects on beta-2 receptors in pulmonary tissue. Sympathomimetics may cause tachycardia, arrhythmia and hypertension. There is therefore a continuing need for therapies which control the elevated intraocular pressure associated with glaucoma.
Prostaglandins, which are metabolite derivatives of arachidonic acid, have recently been pursued for possible efficacy in lowering IOP. Arachidonic acid in the body is converted to prostaglandin G.sub.2, which is subsequently converted to prostaglandin H.sub.2. Other naturally occurring prostaglandins are derivatives of prostaglandin H.sub.2. A number of different types of prostaglandins have been discovered including A, B, D, E, F, G, I and J-series prostaglandins (EP 0 561 073 A1). Of interest in the present invention are compounds which are believed to exhibit IOP lowering mechanisms similar to those exhibited by PGD.sub.2 (formula (I)) and PGF.sub.2.alpha. (formula (II)): ##STR1##
The relationship between prostaglandin DP receptor activation and IOP lowering effects is not well understood. Various publications have reported that DP receptor activation leads to second messenger activation and in particular, to the stimulation of adenylate cyclase and resultant increases in cAMP levels (Thierauch, Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction, Journal of Hypertension, volume 12, pages 1-5 (1994). Regardless of mechanism. PGD.sub.2 has been shown to lower IOP (Nakajima, Effects of Prostaglandin D.sub.2 and its analog, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Ophthalmology, volume 229, pages 411-413 (1991)). Thus, it has been of interest in the field to develop synthetic PGD.sub.2 analogs with IOP lowering efficacy.
Synthetic PGD.sub.2 -type analogs have been pursued in the art (Graefe's Archive Ophthalmology, volume 229, pages 411-413 (1991)). Though some PGD.sub.2 -type molecules lower IOP, these types of molecules have also been associated with undesirable side effects resulting from topical ophthalmic dosing. Such effects have included an initial increase in IOP, conjunctival hyperemia, increases in microvascular permeability, and increases in eosinophile infiltration (Alm, The Potential of Prostaglandin Derivative
REFERENCES:
patent: 3883659 (1975-05-01), Vlattas
patent: 4088779 (1978-05-01), Vlattas
patent: 4133817 (1979-01-01), Lourens et al.
patent: 5574066 (1996-11-01), Chan et al.
Alm, "The Potential Prostaglandin Derivatives in Glaucoma Therapy" Current Opinion in Ophthalmology 4(11):44-50 (1993).
Arndt et al., "Stereospecific Synthesis of Modified Prostaglandins Derived from Carbohydrates. Part 1." S. Afr. J. Chem. 34(4):121-127 (Jun. 1981).
Giuffre, "The Effects of Prostaglandin F.sub.2.alpha. the Human Eye" Graefe's Arch Clin Exp Ophthalmol 222:139-141 (1985).
Hanessian et al., "Total Synthesis of 11-Oxaprostaglandin F.sub.2.alpha. and F.sub.2.beta. " Carbohydrate Research 141(2):221-238 XP000644751 (1985).
Kerstetter et al., "Prostaglandin F.sub.2.alpha. -1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow" American Journal of Ophthalmology 105:30-34 (1988).
Lourens et al., "The Novel Stereospecific Synthesis of 11-oxapros-taglandin F.sub.2.alpha. " Tetrahedron Letters, No. 43:3719-3722 Pergamon Press (1975).
Nakajima et al., "Effects of Prostaglandin D.sub.2 and its Analog, BW245C, on Intraocular Pressure in Humans" Graefe's Arch Clin Exp Ophthalmol 229:411-413 (1991).
Thiem et al., "Synthese von Qxaprostaglandinen aus 1,4:3,6-Dianhydro-D-sorbit" Liebigs Ann. Chem. 2151:2164 XP0006444761 (1985).
Thierauch et al., "Prostaglandins and Their Receptors: II. Receptor Structure and Signal Transduction" Journal of Hypertension 12:1-5 (1994).
Verdoorn et al., "Synthesis of Methyl (5Z,13E(15S)-9.alpha.-acetoxy-15-hydroxy-17-(3-trifluoromethylphenyl)-11-o xa-18,19,20-trinorprosta-5,13-dienoate" S. Afr. Tydskr. Chem. 40(2):134-138 XP000618452 (1987).
Vlattas et al., "Synthesis of 9-Oxaprostaglandins" Tetrahedron Letters No. 51/52:4455-4458, Pergamon Press, 1974.
Vlattas et al., "Synthesis of 11-oxaprostaglandins" Tetrahedron Letters No. 51/52:4451-4454, XP000644759, Pergamon Press, 1974.
Klimko Peter G.
Selliah Robert D.
Alcon Laboratories Inc.
Copeland Barry L.
Trinh Ba K.
LandOfFree
Substituted tetrahydrofuran analogs of prostaglandins as ocular does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted tetrahydrofuran analogs of prostaglandins as ocular , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted tetrahydrofuran analogs of prostaglandins as ocular will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1673314